My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

28.34 -0.19 (-0.67%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >

This Biotech Stock Could Cure Your Portfolio's Pain ↗

December 14, 2025

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

Via The Motley Fool

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗

December 11, 2025

Arcuitis Biotherapeutics (ARQT) exemplifies a high-growth momentum stock in a confirmed technical uptrend, blending strong fundamentals with a robust price structure.

Via Chartmill

Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗

November 21, 2025

The company continues to receive good news from the Food and Drug Administration.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗

November 13, 2025

Via Benzinga

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗

November 10, 2025

ARQT stock combines a strong Minervini Trend Template setup with explosive sales and earnings growth, creating a compelling high-growth momentum opportunity.

Via Chartmill

These stocks are moving in today's session ↗

October 28, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Arcutis Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Arcutis Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Top stock movements in today's session. ↗

October 28, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 28, 2025

Via Benzinga

Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗

October 28, 2025

Via Benzinga

Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗

October 28, 2025

Arcutis Biotherapeutics had an excellent update for investors and its future looks bright.

Via The Motley Fool

Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗

October 28, 2025

Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income.

Via Investor's Business Daily

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

October 28, 2025

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

October 28, 2025

Via Benzinga

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability ↗

October 28, 2025

Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand.

Via Chartmill

Topics Earnings

Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview ↗

October 27, 2025

Via Benzinga

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum ↗

September 16, 2025

Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance.

Via Chartmill

Top 5 Biotech Stocks With Strong Momentum ↗

August 28, 2025

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

Via Benzinga

3 Biotech Catalysts Present Major Opportunity ↗

August 25, 2025

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Via MarketBeat

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum ↗

August 14, 2025

Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors.

Via Chartmill

Arcutis (ARQT) Q2 Revenue Soars 164% ↗

August 07, 2025

Via The Motley Fool

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected ↗

August 06, 2025

Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings.

Via Chartmill

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 25, 2025

Via Benzinga

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis ↗

June 06, 2025

Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema.

Via Benzinga

Analyst Expectations For Arcutis Biotherapeutics's Future ↗

May 23, 2025

Via Benzinga

Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick? ↗

April 24, 2025

A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing?

Via Chartmill

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.